1 |
Hasan SS, Lim KN, Anwar M, et al. Impact of pharmacists' intervention on identification and management of drug-drug interactions in an intensive care setting. Singapore Med J 2012;53(8):526-31.
|
2 |
Smithburger PL, Kane-Gill SL, Seybert AL. Drug-drug interactions in the medical intensive care unit: an assessment of frequency, severity and the medications involved. Int J Pharm Pract 2012;20(6):402-8.
DOI
|
3 |
LeBlanc JM, Seoane-Vazquez EC, Arbo TC, et al. International critical care hospital pharmacist activities. Intensive Care Med 2008;34(3):538-42.
DOI
|
4 |
Kim HA. A Study on the Improvement of Drug Safety for Pharmaceutical Care Disparities in Korea. In: Fall Symposium of Korean Academy of Social & Managed Care Pharmacy, Seoul, Republic of Korea, Nov 6, 2014.
|
5 |
Online. http://www.uptodate.com/crlsql/interact/frameset.jsp (accessed February 1, 2015).
|
6 |
National Cancer Institute. Common terminology criteria for adverse events v4.0 (CTCAE). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (accessed February 1, 2015).
|
7 |
Rivkin A, Yin H. Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients. J Crit Care 2011;26(1):104.e1-6.
DOI
|
8 |
Cash JJ. Alert fatigue. Am J Health-Syst Pharm 2009;66(23):2098-101.
DOI
|
9 |
Kreutz RP, Stanek EJ, Aubert R, et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: The Clopidogrel Medco Outcomes Study. Pharmacotherapy 2010;30(8):787-96.
DOI
|
10 |
Fischer JR, Baer RK. Acute myopathy associated with combined use of corticosteroids and neuromuscular blocking agents. Ann Pharmacother 1996;30(12):1437-45.
DOI
|